Moreover, the 36-month beta value for RDHL is 3.79. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RDHL is 1.27M and currently, short sellers hold a 0.42% of that float. On February 25, 2025, RDHL’s average trading volume was 14.56K shares.
RDHL) stock’s latest price update
The stock of Redhill Biopharma Ltd. ADR (NASDAQ: RDHL) has decreased by -20.54 when compared to last closing price of 4.82. Despite this, the company has experienced a -27.54% fall in its stock price over the last five trading sessions. prnewswire.com reported 2025-02-25 that – Hyloris will pay RedHill an upfront payment and up to $60 million in potential milestone payments, plus up to mid-20s percent royalties on revenues, in return for exclusive rights to develop and commercialize RHB-102 (Bekinda®) across all indications and territories outside the United States, Canada and Mexico – Recent positive UK MHRA advice provided a clear pathway for a UK Marketing Authorization Application (MAA). If approved, RHB-102 could be the first oral 24-hour extended-release ondansetron for the treatment of chemotherapy/radiotherapy-induced nausea and vomiting (CINV/RINV) – RedHill intends to continue development of RHB-102 for FDA approval in the U.S., if granted.
RDHL’s Market Performance
Redhill Biopharma Ltd. ADR (RDHL) has experienced a -27.54% fall in stock performance for the past week, with a -40.53% drop in the past month, and a -40.16% drop in the past quarter. The volatility ratio for the week is 3.65%, and the volatility levels for the past 30 days are at 4.76% for RDHL. The simple moving average for the last 20 days is -29.60% for RDHL stock, with a simple moving average of -55.37% for the last 200 days.
Analysts’ Opinion of RDHL
Many brokerage firms have already submitted their reports for RDHL stocks, with Cantor Fitzgerald repeating the rating for RDHL by listing it as a “Overweight.” The predicted price for RDHL in the upcoming period, according to Cantor Fitzgerald is $22 based on the research report published on August 31, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see RDHL reach a price target of $23. The rating they have provided for RDHL stocks is “Buy” according to the report published on May 18th, 2021.
RDHL Trading at -36.71% from the 50-Day Moving Average
After a stumble in the market that brought RDHL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.11% of loss for the given period.
Volatility was left at 4.76%, however, over the last 30 days, the volatility rate increased by 3.65%, as shares sank -25.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.01% lower at present.
During the last 5 trading sessions, RDHL fell by -9.38%, which changed the moving average for the period of 200-days by -58.24% in comparison to the 20-day moving average, which settled at $5.49. In addition, Redhill Biopharma Ltd. ADR saw -38.33% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RDHL
Current profitability levels for the company are sitting at:
- 1.94 for the present operating margin
- 0.47 for the gross margin
The net margin for Redhill Biopharma Ltd. ADR stands at 3.67. The total capital return value is set at 3.32.
Based on Redhill Biopharma Ltd. ADR (RDHL), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -30.54. The debt to equity ratio resting at 0.57. The interest coverage ratio of the stock is 34.42.
Currently, EBITDA for the company is 26.31 million with net debt to EBITDA at -0.17. When we switch over and look at the enterprise to sales, we see a ratio of -0.67. The receivables turnover for the company is 1.98for trailing twelve months and the total asset turnover is 0.28.
Conclusion
To wrap up, the performance of Redhill Biopharma Ltd. ADR (RDHL) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
